文献速递间质性肺疾病

慢性过敏性肺炎患者中罕见端粒相关基因变异

Rare Protein-Altering Telomere-related Gene Variants in Patients with Chronic Hypersensitivity Pneumonitis.
PubMed 文献 · Am J Respir Crit Care Med · 2019-01-01

本研究在慢性过敏性肺炎(CHP)的两个队列中分析端粒相关基因的罕见蛋白改变变异,发现发现队列11.1%、复制队列8.1%的患者携带此类变异;变异与更短的外周血白细胞端粒长度及显著降低的无移植生存率相关。

要点

  • CHP患者中罕见端粒相关基因变异发生率约8-11%
  • 携带变异者外周血端粒长度显著缩短
  • 变异与无移植生存率显著降低相关

核心结论

  • 相当比例CHP患者携带罕见蛋白改变端粒相关基因变异,与短端粒及无移植生存率降低相关。

研究设计与样本

  • 对两个CHP队列进行下一代测序,分析TERT、TERC、DKC1、RTEL1、PARN、TINF2基因变异。
  • 发现队列144例,复制队列209例;变异定义为次要等位基因频率<0.005且预测损害蛋白功能。
  • 采用Cox比例风险模型分析无移植生存,定量PCR测量外周血白细胞端粒长度。

主要发现

  • 发现队列16/144例(11.1%;95%CI 6.5-17.4)携带合格变异。
  • 复制队列17/209例(8.1%;95%CI 4.8-12.7)携带合格变异。
  • 年龄和祖先调整后,携带变异者端粒长度显著更短:发现队列-561 bp(95%CI -933至-190;P=0.003)。
  • 复制队列端粒长度-612 bp(95%CI -870至-354;P=5.30×10-6)。
  • 无移植生存:发现队列年龄、性别、祖先调整HR 3.73(95%CI 1.92-7.28;P=0.0001);复制队列HR 2.72(95%CI 1.26-5.88;P=0.011)。

临床怎么用

  • 对CHP患者可考虑端粒相关基因检测以识别高风险亚群。
  • 携带罕见蛋白改变变异提示端粒缩短及无移植生存差,需密切随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Rare genetic variants in telomere-related genes have been identified in familial, idiopathic, and rheumatoid arthritis-associated pulmonary fibrosis. Short peripheral blood leukocyte (PBL) telomere length predicts poor outcomes in chronic hypersensitivity pneumonitis (CHP).Objectives: Determine the prevalence and clinical relevance of rare protein-altering variants in telomere-related genes in patients with CHP.Methods: Next-generation sequences from two CHP cohorts were analyzed to identify variants in TERT (telomerase reverse transcriptase), TERC (telomerase RNA component), DKC1 (dyskerin pseudouridine synthase 1), RTEL1 (regulator of telomere elongation helicase 1), PARN (poly[A]-specific RNase), and TINF2 (TERF1-interacting nuclear factor 2). To qualify, variants were required to have a minor allele frequency less than 0.005 and be predicted to be damaging to protein function. Variant status (binary variable) was used in statistical association tests, including Cox proportional hazard models for transplant-free survival. PBL telomere length was measured using quantitative PCR.Measurements and Main Results: Qualifying variants were identified in 16 of 144 patients (11.1%; 95% confidence interval [CI], 6.5-17.4) in the discovery cohort and 17 of 209 patients (8.1%; 95% CI, 4.8-12.7) in the replication cohort. Age- and ancestry-adjusted PBL telomere length was significantly shorter in the presence of a variant in both cohorts (discovery: -561 bp; 95% CI, -933 to -190; P = 0.003; replication: -612 bp; 95% CI, -870 to -354; P = 5.30 × 10-6). Variant status was significantly associated with transplant-free survival in both cohorts (discovery: age-, sex-, and ancestry-adjusted hazard ratio, 3.73; 95% CI, 1.92-7.28; P = 0.0001; replication: hazard ratio, 2.72; 95% CI, 1.26-5.88; P = 0.011).Conclusions: A substantial proportion of patients diagnosed with CHP have rare, protein-altering variants in telomere-related genes, which are associated with short peripheral blood telomere length and significantly reduced transplant-free survival.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Ley B, Torgerson DG, Oldham JM, et al. Rare Protein-Altering Telomere-related Gene Variants in Patients with Chronic Hypersensitivity Pneumonitis. Am J Respir Crit Care Med. 2019. PMID: 31268371. doi:10.1164/rccm.201902-0360OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。